

Palliative Care for End Stage Liver Disease patients

Kat Dobrovolny, MD, MS; VCU HPM Fellow

Palliative Care ECHO, April 2025

I have no financial disclosures to report

Objectives

Define the criteria for palliative medicine involvement in end stage liver disease (ESLD) care

Clarify appropriate triggers for involvement of primary or specialty palliative care

Describe common symptom burden and management in patients with ESLD

Patient case: Mrs. H

62F, PMH notable for ETOH cirrhosis

- hx HAT s/p DDLT (2/2024) c/b hepatic artery pseudoaneurysm s/p coiling, liver infarct, abscess w biliary leak (ongoing)



10/2024

- Admitted with hypercalcemia & concern for sepsis

Mrs. H, continued

Day 16-18

- Primary team schedules oxycodone 2.5mg q6h



Day 18-22

- Dose increased to 5mg q6h scheduled



Day 22

- Palliative care consulted for symptom burden (diffuse pain)

Mrs. H, continued

RASS scores +1/-1

Patient endorses pain "all over"

No palliative care involvement found in EMR prior to liver transplant or current hospitalization

Discontinued scheduled opiates

Allowed for oxycodone 2.5mg q8h PRN in addition to non-opiate therapies

Symptom burden improved as a result

Resource review

PubMed initial search

Current guidelines



("End Stage Liver Disease"[Majr]) AND "Palliative Medicine"[Majr]



Search

[Advanced](#) [Create alert](#) [Create RSS](#)

[User Guide](#)

Sort by: Most recent



Display options

MY CUSTOM FILTERS

No results were found.

PUBLICATION DATE

- ☐ 1 year
- ☐ 5 years
- ☐ 10 years
- ☐ Custom Range

TEXT AVAILABILITY

- ☐ Abstract
- ☐ Free full text
- ☐ Full text



Your search was processed without automatic term mapping because it retrieved zero results.



("End Stage Liver Disease"[Majr]) AND "Palliative Care"[Majr]



Search

Advanced Create alert Create RSS

User Guide

Save

Email

Send to

Sort by:

Most recent



Display options



MY CUSTOM FILTERS

39 results




Page

1

of 4



RESULTS BY YEAR



PUBLICATION DATE

- ☐ 1 year
- ☐ 5 years
- ☐ 10 years
- ☐ Custom Range

TEXT AVAILABILITY

- ☐ Abstract
- ☐ Free full text
- ☐ Full text



1

Cite
Share

Palliative care and end stage liver disease: A survey study comparing perspectives of hepatology and palliative care physicians and clinical scenarios that could require palliative care intervention.

Oliveira HM, Ramos JP, Rego F, Nunes R.

Clin Res Hepatol Gastroenterol. 2024 Aug;48(7):102416. doi: 10.1016/j.clinre.2024.102416. Epub 2024 Jul 8.

PMID: 38986810 **Free article.**



2

Cite
Share

Palliative care and end stage liver disease: A cohort analysis of palliative care use and factors associated with referral.

Oliveira HM, Miranda HP, Rego F, Nunes R.

Ann Hepatol. 2024 Sep-Oct;29(5):101518. doi: 10.1016/j.aohp.2024.101518. Epub 2024 Jun 6.

PMID: 38851396 **Free article.**



3

Cite
Share


When Is the Optimal Time to Refer Patients with End-Stage Liver Disease to Palliative Care Specialists? #481.

Ghoshal A, Marks S, Esteban JP.

J Palliat Med. 2024 Jun;27(6):813-815. doi: 10.1089/jpm.2024.0111. Epub 2024 Apr 30.

PMID: 38686513 No abstract available.

RESULTS BY YEAR



PUBLICATION DATE

- ☐ 1 year
- ☒ 5 years
- ☐ 10 years
- ☐ Custom Range

TEXT AVAILABILITY

- ☐ Abstract
- ☐ Free full text
- ☐ Full text

ARTICLE ATTRIBUTE

Filters applied: in the last 5 years. [Clear all](#)

1

Cite

Share

[Palliative care and end stage liver disease: A survey study comparing perspectives of hepatology and palliative care physicians and clinical scenarios that could require palliative care intervention.](#)

Oliveira HM, Ramos JP, Rego F, Nunes R.

Clin Res Hepatol Gastroenterol. 2024 Aug;48(7):102416. doi: 10.1016/j.clinre.2024.102416. Epub 2024 Jul 8.

PMID: 38986810 [Free article.](#)



2

Cite

Share

[Palliative care and end stage liver disease: A cohort analysis of palliative care use and factors associated with referral.](#)

Oliveira HM, Miranda HP, Rego F, Nunes R.

Ann Hepatol. 2024 Sep-Oct;29(5):101518. doi: 10.1016/j.aohep.2024.101518. Epub 2024 Jun 6.

PMID: 38851396 [Free article.](#)



3

Cite

Share

[When Is the Optimal Time to Refer Patients with End-Stage Liver Disease to Palliative Care Specialists? #481.](#)








Ghoshal A, Marks S, Esteban JP.

J Palliat Med. 2024 Jun;27(6):813-815. doi: 10.1089/jpm.2024.0111. Epub 2024 Apr 30.

PMID: 38686513 [No abstract available.](#)

PRACTICE GUIDANCE

AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis

 Rogal, Shari S.^{1,2};  Hansen, Lissi³;  Patel, Arpan^{4,5};  Ufere, Nneka N.⁶;  Verma, Manisha⁷;  Woodrell, Christopher D.^{8,9};  Kanwal, Fasiha^{*,10,11}


Author Information 

Hepatology 76(3):p 819-853, September 2022. | DOI: 10.1002/hep.32378







 Metrics

Rogal SS, Hansen L, Patel A, Ufere NN, Verma M, Woodrell CD, et al. AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. *Hepatology*. 2022;76:819–853. <https://doi.org/10.1002/hep.32378> RogalSS, HansenL, PatelA, UfereNN, VermaM, WoodrellCD, et al. AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. *Hepatology*. 2022;76:819–853. <https://doi.org/10.1002/hep.32378>

CLINICAL PRACTICE UPDATE · Volume 19, Issue 4, P646-656.E3, April 2021

 Download Full Issue

AGA Clinical Practice Update on Palliative Care Management in Cirrhosis: Expert Review

Puneeta Tandon *  · Anne Walling  · Heather Patton  · Tamar Taddei 

Affiliations & Notes  Article Info 

Palliative Care and Cirrhosis

Most current
recommendations
pertain to
decompensated
cirrhosis, ESLD


Specific
recommendations
regarding diagnosis
and management of
commonly reported
symptoms

Primary vs Specialty Palliative Care



TABLE 1 - Key similarities and differences between primary palliative care, specialty palliative care, hospice, and advance care planning

	Primary palliative care	Specialty palliative care	Hospice	Advance care planning
Primary focus	Quality of life, symptoms, psychosocial and spiritual support	Quality of life, symptoms, psychosocial and spiritual support	Quality of life, symptoms, psychosocial and spiritual support	Longitudinal process of discussing and documenting patient values and preferences around their care (e.g., end of life); identifying surrogate decision makers
Delivered by	Primary or specialist treating teams	Palliative care clinicians/teams, as consultants or embedded within practices	Usually private hospice agencies (or within Veterans Administration system for veterans)	Any clinician; persons can also complete some documents on their own.
Timing	Any time a need is identified	Any time a need is identified	Prognosis ≤6 months	Can be addressed early in the illness course and revisited on a regular basis and when there are major clinical changes
Location	Anywhere under the care of treating team	Inpatient, outpatient, community (home, nursing home)	Home, nursing home, inpatient (limited time for uncontrolled symptoms)	Anywhere
Reimbursement	Routine CMS billing	Routine CMS billing	Capitated payment model through Medicare Part A	Can be reimbursed with ACP billing codes: 99497 (first 30 min) 99498 (additional 30 min)



The comprehensive primary palliative care toolkit



Enhance ACP and communication skills (BPA 4,7)

See examples of online provider and patient facing tools in Supplementary Table 1 (BPA 4)



Establish care pathways with specialty palliative care (BPA 9)



Carry out the fundamentals of assessment and management

Symptoms (BPA 3, Table 3)

(e.g., ESAS including pruritus, PHQ-2, Distress Thermometer, a Quality of Life Scale)

Prognosis, functional status (BPA 6)

(e.g., ask– “Compared to last year, have you noticed any changes in your ability to carry out your day-to-day tasks?” Is this change happening over years? months? days?”, measure– MELD-Na, Karnofsky Index, Liver Frailty Index)

ACP readiness → ACP/GCD (BPA 6,7)

(e.g., ask–“I want to share with you my understanding of where things are at with your illness...” Is this okay with you?)




Caregiver needs (BPA 5)

(e.g., ask– “I know this must be hard on you. How are you doing?”, measure– Caregiver Strain Index, Zarit Burden Interview)



Access specialty services when needed (BPA 9,10)


(e.g., refer to specialty palliative care, refer to hospice)



Rogal, Shari S.1,2; Hansen, Lissi3; Patel, Arpan4,5; Ufere, Nneka N.6; Verma, Manisha7; Woodrell, Christopher D.8,9; Kanwal, Fasiha*, 10,11. AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. Hepatology 76(3):p 819-853, September 2022. | DOI: 10.1002/hep.32378

Decompensated liver cirrhosis

Objective measures



Defining ESLD

MELD-Na

- Need for dialysis
- Creatinine
- Bilirubin
- INR
- Na

90-day mortality estimates

- >32: 65-66% mortality


Defining ESLD


Child-Pugh

- Bilirubin
- Albumin
- INR
- Ascites
- Presence/severity of encephalopathy

Class A, B, C

- A: life expectancy >15 years
- B: indication for transplant evaluation
- C: life expectancy 1-3 years





Original Article |  [Free Access](#)

Development of a novel frailty index to predict mortality in patients with end-stage liver disease

Jennifer C. Lai  Kenneth E. Covinsky, Jennifer L. Dodge, W. John Boscardin, Dorry L. Segev, John P. Roberts, Sandy Feng

First published: 19 April 2017 | <https://doi.org/10.1002/hep.29219> | Citations: 250

Liver Frailty Index®

Inputs: For instructions, see ⓘ below.

1. Gender:

☐ Male ☐ Female

2. ⓘ Dominant hand grip strength (kg):

attempt 1:

attempt 2:

attempt 3:

Avg:

kg

3. ⓘ Time to do 5 chair stands:

sec

4. ⓘ Seconds holding 3 position balance:

Side:

SemiTandem:

Tandem:

Total:

sec

Results:


[refresh results](#)

The Liver Frailty Index® is ____

Decimal precision:

2









Fig. 3. The three typical end-of-life trajectories (adapted from [Murray and McLoughlin, 2012](#), Fig. 3.1 cited [Murray and Sheikh, 2008](#)).

(left) image source: Teggi, Diana. (2018). Unexpected death in ill old age: An analysis of disadvantaged dying in the English old population. *Social Science & Medicine*. 217. 10.1016/j.socscimed.2018.09.048.



Decompensated liver cirrhosis

Subjective measures

PHQ-9	ESAS	PROMIS-29, PROMIS-CAT	LDSI	CLDQ	SF-LDQOL
Anhedonia, feeling down, sleep, feeling tired, appetite, feeling bad about self, concentration, activity, suicidality	Pain, fatigue, myalgia, sexual dysfunction, anxiety, sleep disturbance, appetite, well-being, dyspnea, pruritis	Anxiety/fear, cognitive function, depression/sadness, fatigue, instrumental support, pain interference, physical function, sleep disturbance, social roles	Itch, joint pain, abdominal pain, daytime sleepiness, worry about family situation, decreased appetite, depression, fear of complications, jaundice	Abdominal symptoms, fatigue, systemic symptoms, activity, emotional function, worry	Symptoms, effects of liver disease, memory/concentration, sleep, hopelessness, distress, loneliness, stigma of liver

SF-36	Distress Thermometer (DT)	NHP	LC-PROM	LDQOL	SIP
Vitality, physical role functioning, bodily pain, general health perception, physical function, social role functioning, emotional role functioning, mental health	Overall assessment of distress plus practical problems, family problems, emotional problems, spiritual/religious concerns, physical problems	<p>I: energy, sleep, emotions, pain, mobility, social isolation</p> <p>II: paid employment, housework, hobbies, family life, social life, sex life, holidays</p>	Physical, psychological, social, therapeutic	Symptoms, effects on activities of daily living, concentration, memory, sexual function, sexual problems, sleep, loneliness, hopelessness, quality of social interaction, health distress, self-perceived stigma of liver disease	Sleep and rest, eating, work, home management, recreation and pastimes, ambulation, mobility, body care and movement, social interaction, alertness behavior, emotional behavior, communication

Common Symptoms in ESLD

Pain

Liver-associated mechanical pain, Inflammatory pain

- Ex: splenomegaly, ascites, and hepatic capsular stretch or indirectly because of elevation of proinflammatory cytokines

Non-liver-associated pain

- Common ex: neuropathic, musculoskeletal

Pain Management

Multidisciplinary approach

- Palliative care, psychiatry, pain management, pharmacy, physical and occupational therapy, or social work
- Mindfulness/meditation, CBT, nerve block when appropriate

Evaluate for, and treat reversible causes

- Ascites
- Local infection
- MSK injury

Medications

- Nociceptive vs neuropathic regimen
- Lowest effective dose

Ascites

Renal sodium retention

Worsens with disease progression

Often associated with pain, cramping, dyspnea

Management

- Diet and medication optimization
- Large volume paracentesis (LVP)
- TIPS
- Abdominal drains

Hepatic Encephalopathy (HE)

Range of neuropsychiatric abnormalities resulting from the accumulation of neurotoxic substances in the bloodstream of patients with liver dysfunction

Diagnosis of exclusion

Severe impacts on caregiving burden, patient quality of life

HE: Management

Lactulose

- Promotes excretion of ammonia via an osmotic effect
- Titrate to 2-3 bowel movements per day
- Associated with bloating, abdominal pain, diarrhea

Rifaximin

- Antibiotic that reduces ammonia production by targeting and eliminating ammonia-producing bacteria in the colon

Dyspnea: Etiology

Patient report of shortness of breath in ~47-88% of cirrhotic patients

- Ascites, volume overload (refractory to diuretics), hepatopulmonary syndrome, portopulmonary syndrome, infection, anxiety

Subjective markers:

- Difficulty pulling in a breath, increased effort of breathing, increased rate of breathing, overall distress

Objective markers:

- Hypoxia, tachypnea, use of accessory muscles

Dyspnea: Management

Pharmacologic treatment limited to end-of-life care

- Opiates
- Benzos

Non-pharmacologic treatments

- Fan for stimulation of trigeminal nerve
- Use of supplemental oxygen
- Mindfulness exercises

Muscle Cramps: Etiology

Present in ~50% of patients

Common causes:

- Ascites complicated by spontaneous bacterial peritonitis (SBP) or electrolyte disturbances

Muscle Cramps: Management

Treat underlying etiology

- SBP with antibiotics
- Electrolyte abnormalities with repletion, adjustment of diet

Vitamins

- Vitamin E, taurine, L-carnitine

Low dose baclofen

- Refractory cases

Pruritus

Multiple causes

- Ranging from topical irritants and dry skin to biliary stasis

Non-pharmacological therapy

- Topical emollients and creams

Lifestyle modifications

- Avoiding hot showers/baths, harsh soaps and detergents, wearing loose clothing

Pharmacological therapy

- Cholestyramine
- Antihistamines are typically avoided due to side effect profile

Nausea, Vomiting: Etiology

Multifactorial

- Physical distention/discomfort from ascites
- Electrolyte imbalances
- Adrenal insufficiency
- Pharmacological causes
- Underlying gastrointestinal disorders (i.e. GERD)

Nausea, Vomiting: Management

Behavioral

- Small, frequent meals
- Aromatherapy, peppermint or alcohol wipes

Pharmacological

- Ondansetron, haloperidol/olanzapine, metoclopramide, etc.
- Treat underlying etiology

Sleep Disturbances

Non-pharmacological therapy

- Sleep hygiene, daily exercise
- Cognitive behavioral therapy

Pharmacological therapy

- Melatonin
- Hydroxyzine
- Trazodone
- Avoid benzodiazepines or hypnotics

Fatigue: Etiology

Evaluate for underlying factors

- Hypothyroidism
- Adrenal insufficiency
- Depression
- Sleep disorders

Fatigue: Management

Non-pharmacological

- Daily exercise; physical therapy assessment
- Evaluate for underlying etiology (if hypothyroid, adrenal, etc.)

Pharmacological

- Insufficient evidence for stimulants in cirrhotic patients
- Ex: modafinil, methylphenidate

Depression, Anxiety: Etiology

Multifactorial

- Underlying mood disorder
- Existential suffering
- Vitamin deficiencies
- Encephalopathy
- Sleep disturbances
- Hormonal
- Housing, food insecurity
- Financial instability

Depression, Anxiety: Management

Non-pharmacological

- Psychosocial support
- Multidisciplinary teams including psychiatry, counseling, social work, chaplain, palliative care providers

Pharmacological

- Selective norepinephrine reuptake inhibitors (SNRIs)
- Selective serotonin reuptake inhibitors (SSRIs)
- Benzos

Sexual Dysfunction

Screen for comorbidities

Decreasing use of alcohol, tobacco

Limited data for female patients

Erectile dysfunction

- Tadalafil

Criteria for hospice

In patients with decompensated cirrhosis

Patients should show both:

Prothrombin
time
prolonged $>5s$
over control
or INR >1.5



Serum
albumin
 $<2.5g/dL$

In addition to supporting evidence from the following:

- Ascites, refractory to treatment or patient noncompliant
- SBP
- Hepatorenal syndrome
- Elevated Cr and BUN with oliguria
- HE, refractory to treatment or patient noncompliant
- Recurrent variceal bleeding, despite intensive therapy

Documentation of the following to support eligibility for hospice care:

- Progressive malnutrition
- Muscle wasting with reduced strength and endurance
- Continued active alcohol use
- HCC
- HBsAg positive
- Hepatitis C refractory to treatment
- MELD score >21
- Child-Pugh score >12

Back to our patient case, Mrs. H

Patient without specialty palliative care until time of hospitalization

Is this due to...

Patient
preference?

Provider
preference?

Lack of
specialist
availability?

Not knowing
resources
available to
ESLD
patients?

Initially low
symptom
burden?

Moving forward

Optimizing Palliative Care Involvement

Identifying local
billing codes

Prescreening
surveys
completed by
ancillary staff

Development of
multidisciplinary
teams

Timely referrals to
hospice based on
aforementioned
criteria

Resources

- Rogal, Shari S.^{1,2}; Hansen, Lissi³; Patel, Arpan^{4,5}; Ufere, Nneka N.⁶; Verma, Manisha⁷; Woodrell, Christopher D.^{8,9}; Kanwal, Fasiha*,^{10,11}. AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. *Hepatology* 76(3):p 819-853, September 2022. | DOI: 10.1002/hep.32378
- AGA Clinical Practice Update on Palliative Care Management in Cirrhosis: Expert Review. Tandon, Puneeta et al. *Clinical Gastroenterology and Hepatology*, Volume 19, Issue 4, 646 - 656.e3
- Lai JC, Covinsky KE, Dodge JL, Boscardin WJ, Segev DL, Roberts JP, Feng S. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. *Hepatology*. 2017 Aug;66(2):564-574. doi: 10.1002/hep.29219. Epub 2017 Jun 28. PMID: 28422306; PMCID: PMC5519430.
- Hashmi IN, Lee HM, Wedd JP, Sterling RK, Dulong-Rae TE, Cassel JB, Cyrus JW, Fletcher JJ, Noreika DM. A narrative review of supportive and end of life care considerations in advanced hepatocellular carcinoma. *Ann Palliat Med* 2023;12(6):1260-1274. doi: 10.21037/apm-23-416

Questions?

